Details of the Drug
General Information of Drug (ID: DMZCA15)
Drug Name |
Cynooxide anion
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Fulminic acid; formonitrile oxide; Knallsaeure; HCNO; Hydrogen cyanide N-oxide; H-C#NO; formonitrile-N-oxide; [C(H)NO]; [CH(NO)]; (methylidyneammoniumyl)oxidanide; methylidyne(oxo)-lambda(5)-azane; hydrido(oxidonitrato-N)carbon; hydrido(nitrosyl-kappaN)carbon; CHEMBL185198; CHEBI:29813; 51060-05-0; Cynooxide anion; Formnitrile oxide; AC1LAVEA; CTK1G9581; DTXSID30334603; BDBM50152965; formonitrile oxideformonitrile-N-oxidehydrido(nitrosyl-kappaN)carbonhydrido(oxidonitrato-N)carbon
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 43.025 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||